La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Abeona Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Abeona Therapeutics..

Abeona Therapeutics (NASDAQ:ABEO) Azioni, Catena delle Opzioni

Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Inc

Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 57.5 percent. This is a 31.25 percent decrease over losses of $(0.48) per share from the same period last year.

Earnings

Earnings Misses

News

ABEO

Abeona Therapeutics Q3 2024 GAAP EPS $(0.63) Misses $(0.40) Estimate

Abeona Therapeutics Announces FDA Acceptance Of BLA Resubmission For Pz-cel In Recessive Dystrophic Epidermolysis Bullosa

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and maintains $18 price target.

Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target

Biotech

Health Care

General

Abeona Therapeutics Has Resubmitted Its Biologics License Application To The FDA For Prademagene Zamikeracel (Pz-cel), Its Investigational Autologous Cell-based Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.

The Centers For Medicare And Medicaid Services Has Granted A Product-specific Procedure Code Icd-10-PCS For Abeona Therapeutics' Prademagene Zamikeracel (Pz-cel), Investigational Autologous Cell-based Gene Therapy Currently In Development For Recessive Dystrophic Epidermolysis Bullosa

WIIM

Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

Earnings Beats

Abeona Therapeutics Q2 EPS $(0.26) Beats $(0.36) Estimate, Cash Balance $123M

Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024

Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potential use in certain ophthalmology indications, with an option to take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon&#39;s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204. Beacon will be responsible for the development and commercialization of all licensed products. The targets for which Beacon would receive rights under its non-exclusive license agreement are distinct from those currently in development at Abeona.

Contracts

Abeona Therapeutics And Beacon Therapeutics Announced An Agreement By Which Beacon Will Evaluate Abeona's Patented AAV204 Capsid For The Development And Commercialization Of Potential Gene Therapies For Select Ophthalmology Indications

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $15.

Initiation

HC Wainwright & Co. Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $15

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 12.83% to $0.33. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

ARAY

COSM

CPHI

Intelligent Bio Solutions Inc. - Common Stock

INBS

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

ONMD

PHGE

RSLS

VEEV

VIRI

12 Health Care Stocks Moving In Thursday's After-Market Session

Stifel analyst Dae Gon Ha initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $21.

Stifel Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $21

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and lowers the price target from $28 to $21.

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21

Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.

Guidance

Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026

Abeona Therapeutics Q1 2024 GAAP EPS $(1.16) Misses $(0.51) Estimate

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), with a pric...

Buy Rating on Abeona Therapeutics Bolstered by Positive Medicare Decisions and FDA Approval Progress

The latest announcement is out from Abeona Therapeutics (ABEO). Abeona Therapeutics Inc. has strengthened its Board of Directors with the appointme...

Abeona Therapeutics Enhances Board with Industry Experts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abeona Therapeutics (ABEO – Research Report), Cycl...

Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Abeona Therapeutics resubmits biologics license application for pz-cel to FDA

Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment

Reports Q3 revenue $0 vs. $0 last year. "With the acceptance of our Biologics License Application resubmission for pz-cel, we are ramping up our co...

Abeona Therapeutics reports Q3 EPS (63c) vs. (48c) last year

Cash, cash equivalents, short-term investments and restricted cash totaled $110.0 million as of September 30, 2024. As of June 30, 2024, cash, cash...

Abeona Therapeutics expects cash to fund operations into 2026

Abeona Therapeutics Inc ( ($ABEO) ) has released its Q3 earnings. Here is a breakdown of the information Abeona Therapeutics Inc presented to its i...

Abeona Therapeutics Reports Q3 2024 Financial Highlights

Earnings week ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and more

AVXL

AYRO

BEKE

BIDU

BTBT

BZUN

CMCM

CPRT

CRNC

CYCC

EBON

ESLT

ESTC

FUTU

GALT

GASS

IMMR

INTU

KEYS

KNDI

MBOT

NEGG

NNDM

NNOX

NTAP

NVDA

OCSL

OGEN

PANW

ROST

SBLK

SNOW

TCOM

TCRT

TWST

UAVS

VIPS

WKHS

XPEV

Press Releases

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Management

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Markets

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Abeona Therapeutics

Abeona Therapeutics (ABEO) Opzioni

Abeona Therapeutics (NASDAQ:ABEO) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO